Brexit: EU Countries Dragging Feet On At-Risk Medicines
Executive Summary
The EU regulatory network is finding it difficult to identify non-centrally authorized medicines that are at risk of Brexit-related shortages, a workshop on medicines availability has heard.
You may also be interested in...
Big Share Of EU Decentralized Procedures Still Seeking Post-Brexit Home
Progress is being made with redistributing UK rapporteurships for non-centrally approved medicines, but companies need to keep up the momentum if all procedures are to be reallocated to other EU countries by the Brexit date of March 29, 2019.
UK's No-Deal Brexit Plans Revealed For Pharma Sector
The UK government has published “technical notices” explaining what would change in the drug regulatory arena in the event of a no-deal Brexit, and what stakeholders need to do to prepare. Companies will be expected to stockpile medicines in the immediate run-up to the UK's departure from the EU.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.